{
}
Biopharma IPOs are experiencing a surge, with companies like Septerna and Ceribell achieving significant post-IPO price increases. This success is raising hopes that more tech-related firms will follow suit, as venture capital and hedge fund investments in these biopharma companies remain strong.
UBS has raised its price target for UPS from $159 to $170, maintaining a "Buy" rating. Analyst Thomas Wadewitz noted improvements in the logistics company's third quarter but expressed caution regarding macroeconomic impacts on freight volumes and earnings for 2025 and 2026.
UBS has raised its price target for UPS from $159 to $170 while maintaining a "Buy" rating. Analyst Thomas Wadewitz noted improvements in the logistics company's third quarter but expressed caution regarding macroeconomic impacts on freight volumes and earnings for 2025 and 2026.
UBS has maintained its 'Buy' rating for UPS, setting a target price of $159. Analyst Thomas Wadewitz noted a positive shift for the logistics company in the third quarter, which is expected to bolster the share price.
Upstream Bio has priced its IPO at $255 million, selling 15 million shares at $17 each, to fund the development of its antibody drug targeting respiratory diseases. The company aims to challenge existing asthma treatments, with plans to report Phase 2 results for its drug, verekitug, in 2025. This IPO reflects a growing investor interest in immunology-focused biotech firms, with a notable increase in offerings this year.
Upstream Bio, Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biopharma ipo success sparks hopes for tech sector public offerings
United States Dollar
Upstream Bio, Inc.
Septerna, Inc.
CeriBell, Inc.
MBX Biosciences, Inc.
BioAge Labs, Inc.
Zenas BioPharma, Inc.
Bicara Therapeutics Inc.
Cormorant Asset Management
Redmile Group
RA Capital Management
OrbiMed Advisors
Deep Track Biotechnology Master Fund
Show more
20:15 31.10.2024
ubs raises ups price target to 170 dollars maintaining buy rating
12:34 25.10.2024
UBS raises UPS price target to 170 dollars maintains buy rating
12:34 25.10.2024
ubs maintains buy rating for ups with target price of 159 dollars
18:40 24.10.2024
upstream bio raises 255 million in ipo to develop asthma drug
United States Dollar
Upstream Bio, Inc.
Camp4 Therapeutics Corporation
AstraZeneca PLC
Astellas Pharma Inc.
Amgen Inc.
USA
William Blair
Astellas Pharma
Show more
02:07 11.10.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Banking Regulations
Market Analysis and Predictions
Industry Mergers & Acquisitions
Global Trade Developments
Energy Sector Developments
Startups & Entrepreneurship
Government Policies
Supply Chain Management
Domestic Politics
Financial Scams and Security
Central Bank Actions
Government Economic Policies
Hedge Funds & Private Equity
Countries:
Companies:
Tesla, Inc.
Barclays PLC
JPMorgan Chase & Co.
BNP Paribas SA
Apple Inc.
Bank of America Corporation
UBS Group AG
Morgan Stanley
NVIDIA Corporation
Raiffeisen Bank International AG
Capital One Financial Corporation
Deutsche Bank RV Global PP
The Goldman Sachs Group, Inc.
Citigroup Inc.
Amazon.com, Inc.
SpaceXCoin USD
Commerzbank AG
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
Berkshire Hathaway Inc.
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
Swiss Franc
British Pound Sterling
Vietnamese Đồng
Hong Kong Dollar
Australian Dollar
United Arab Emirates Dirham
Japanese Yen
Singapore Dollar
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Russian Ruble
Ghanaian Cedi
Canadian Dollar
People: